Get notified of page updates

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

Clinicaltrials.gov identifier:
NCT03043313

Study Contact Information:

For more information, contact Seagen Trial Information Support at 866-333-7436 or by email. 

PRINTER FRIENDLY PAGE
Overview
Who Can Join
Contact
Glossary on
off

About the Study

This is a study for people who have been diagnosed with (HER2+) colorectal cancer (mCRC).  The goal of this study is to look at how well the drug tucatinib (Tukysa) works to improve outcomes when given with trastuzumab (Herceptin), versus how well tucatinib works when administered by itself. NOTE: This study is no longer enrolling patients. 

This Study is Open To:

NOTE: This study is no longer enrolling patients. 

This Study is NOT Open To:

Study Contact Information:

For more information, contact Seagen Trial Information Support at 866-333-7436 or by email. 

Clinicaltrials.gov identifier:
NCT03043313

Study Contact Information:

For more information, contact Seagen Trial Information Support at 866-333-7436 or by email. 

PRINTER FRIENDLY PAGE